Otsuka Pharmaceutical Co., Ltd. et al v. Alvogen, Inc. et al > Summary
Court Case Number 1:25-cv-00188
Filing Date Feb 14, 2025
Court Delaware District Court
Status Unknown
JudgesJennifer L. Hall
Plaintiff Attorneys
8H. Lundbeck A/S
Attorney Name: Steven J. Balick
Ashby & Geddes
Otsuka Pharmaceutical
Attorney Name: Sasha Hoyt
Finnegan, Henderson, Farabow, Garrett & Dunner
H. Lundbeck A/S
Attorney Name: Andrew C. Mayo
Ashby & Geddes
Otsuka Pharmaceutical
Attorney Name: Erin M. Sommers
Finnegan, Henderson, Farabow, Garrett & Dunner
Otsuka Pharmaceutical
Attorney Name: James B. Monroe
Finnegan, Henderson, Farabow, Garrett & Dunner
Otsuka Pharmaceutical
Attorney Name: Jeanette M. Roorda
Finnegan, Henderson, Farabow, Garrett & Dunner
Otsuka Pharmaceutical
Attorney Name: Laura E. Brashear
Finnegan, Henderson, Farabow, Garrett & Dunner
Otsuka Pharmaceutical
Attorney Name: Melanie M. Magdun
Finnegan, Henderson, Farabow, Garrett & Dunner
Defendant Attorneys
Almaject, Inc.
Attorney Name: Nathan R. Hoeschen
Shaw Keller LLP
Related Patents
| Doc No | Title | Issue date |
|---|---|---|
| 11648347 | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient | May 16, 2023 |
| 11400087 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Aug 2, 2022 |
| 11344547 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | May 31, 2022 |
| 11154553 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Oct 26, 2021 |
| 10980803 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Apr 20, 2021 |
| 10525057 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Jan 7, 2020 |
